【摘要】 目的:评价美金刚对轻中度阿尔茨海默病(AD)患者认知功能的改善作用。方法:将63例轻中度AD[简易精神状态量表(MMSE)评分界于10～26分]患者随机分为2组,美金刚治疗组32例,多奈哌齐治疗组31例。美金刚治疗组给予盐酸美金刚,起始剂量为5mg/d,前3周以每周5mg递增,从第4周开始,剂量维持在20mg/d;多奈哌齐治疗组给予安理申5mg/d,4周后将剂量改为10mg/d。2组观察总疗程均为18周。2组患者分别在治疗前,治疗后4、12和18周进行MMSE量表及AD评估量表的认知分量表(ADAS-cog)测评。结果:MMSE(F时间=11.232,P<0.001)和ADAS-cog(F时间=13.717,P<0.001)均显示2组评分在治疗前,治疗后4、12和18周4个时间点上有差异,并且认知功能逐渐好转;但2组间未见差异(MMSE:F组间=3.563,P=0.062;ADAS-cog:F组间=3.247,P=0.068)。结论:美金刚可以改善轻中度AD患者的认知功能,与多奈哌齐的疗效相似。更多还原

【Abstract】 Aim:To evaluate clinical efficacy of memantine in treatment of the patients with mild to moderate Alzheimer’s disease(AD).Methods:A total of 63 patients with mild to moderate AD [Mini Mental State Examination(MMSE) total scores between 10 and 26]were randomly divided into two groups:memantine group(n = 32,treated with memantine by 5 mg/d in the 1st week,added to 10 mg/d in the following 2 weeks,and then 20 mg/d between the 4th to the 18th week) and donepezil group(n = 31,treated with donepezil 5 mg/d from the 1st to the 3rd week,10 mg/d from the 4th to the 18th week).MMSE and Alzheimer’s Disease Assessment Scale-cognition(ADAS-cog) scales were used to evaluated cognitive function at the 0,4th,12th,18th week respectively.Results:There were significant improvements at the 0,4th,12th and 18th weeks in both groups assessed with MMSE(Ftime = 11.232,P < 0.001) and ADAS-cog(Ftime = 13.717,P < 0.001).However there were no significant differences in scores between the two groups(MMSE:Fgroup = 3.563,P = 0.062;ADAS-cog:Fgroup = 3.247,P = 0.068).Conclusion:Memantine could improve the cognition of patients with mild to moderate AD and has a similar effect as donepezil.更多还原